Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Dimethyl fumarate therapy reduces memory T cells and the CNS migration potential in patients with multiple sclerosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The Effects of Exo- and Endocannabinoids in Multiple Sclerosis

    Publikation: Bog/antologi/afhandling/rapportPh.d.-afhandling

Vis graf over relationer

BACKGROUND: Dimethyl fumarate (DMF) is a disease-modifying therapy for patients with relapsing-remitting multiple sclerosis (RRMS). T cells are major contributors to the pathogenesis of RRMS, where they regulate the pathogenic immune response and participate in CNS lesion development.

OBJECTIVES: In this study we evaluate the therapeutic effects of DMF on T cell subpopulations, their CNS migration potential and effector functions.

METHODS: Blood and CSF from untreated and DMF-treated patients with RRMS and healthy donors were analyzed by flow cytometry.

RESULTS: DMF reduced the prevalence of circulating proinflammatory CD4+ and CD8+ memory T cells, whereas regulatory T cells were unaffected. Furthermore, DMF reduced the frequency of CD4+ T cells expressing CNS-homing markers. In coherence, we found a reduced recruitment of CD4+ but not CD8+ T cells to CSF. We also found that monomethyl fumarate dampened T cell proliferation and reduced the frequency of TNF-α, IL-17 and IFN-γ producing T cells.

CONCLUSION: DMF influences the balance between proinflammatory and regulatory T cells, presumably favoring a less proinflammatory environment. DMF also reduces the CNS migratory potential of CD4+ T cells whereas CD8+ T cells are less affected. Altogether, our study suggests an anti-inflammatory effect of DMF mainly on the CD4+ T cell compartment.

OriginalsprogEngelsk
TidsskriftMultiple Sclerosis and Related Disorders
Vol/bind37
Sider (fra-til)101451
ISSN2211-0348
DOI
StatusUdgivet - jan. 2020

Bibliografisk note

Copyright © 2019 Elsevier B.V. All rights reserved.

ID: 61516620